Complement Fragment 3a Priming of Umbilical Cord Blood Progenitors: Safety Profile  by Brunstein, Claudio G. et al.
Biol Blood Marrow Transplant 19 (2013) 1474e1479American Society for Blood
ASBMT
and Marrow TransplantationComplement Fragment 3a Priming of Umbilical Cord Blood
Progenitors: Safety Proﬁle
Claudio G. Brunstein 1,*, David H. McKenna 2, Todd E. DeFor 1,
Darin Sumstad 3, Philip Paul 4, Daniel J. Weisdorf 1, Mariusz Ratajczak 5,
Mary J. Laughlin 4,6, John E. Wagner 1
1Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, Minnesota
2Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
3Molecular and Cellular Therapy Center, Minneapolis, Minnesota
4Cleveland Cord Blood Center, Cleveland, Ohio
5 Stem Cell Institute, University of Louisville, Louisville, Kentucky
6Department of Medicine, Section of Stem Cell Transplantation, University of Virginia, Charlottesville, VirginiaArticle history:
Received 19 June 2013
Accepted 15 July 2013
Key Words:
Umbilical cord blood
Priming
Engraftment
ChimerismFinancial disclosure: See Acknowl
* Correspondence and reprint re
Department of Medicine, Mayo M
Minneapolis, MN, 55455.
E-mail address: bruns072@umn
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Preclinical data showed that priming CD34þ hematopoietic progenitor cells with complement fragment 3a
(C3a) improved homing and engraftment. Thus, we hypothesized that priming of umbilical cord blood (UCB)
hematopoietic progenitors with C3a would facilitate homing and could potentially be used to address the
need for improved engraftment after UCB transplantation. We primed 1 of 2 UCB units for double UCB
transplantation after nonmyeloablative conditioning. This design provided adequate safety and the potential
to observe skewed long-term chimerism in favor of the C3a-primed unit as a surrogate measure of efﬁcacy.
C3a priming of 1 UCB unit did not result in infusional toxicity. Increased grades 1 to 3 hypertension were the
only infusional adverse events observed in 9 (30%) patients. We observed no activation of inﬂammatory or
coagulation pathways downstream of C3a. As tested, C3a priming did not impair engraftment, but did not
skew chimerism toward the treated unit. As compared with historical controls, mortality and survival were
not adversely affected. Thus, before any additional clinical studies, C3a priming to promote engraftment will
require further preclinical optimization.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Umbilical cord blood (UCB) is an established source of
hematopoietic stem cells for transplantation of patients with
advanced and high-risk hematological diseases. Although
outcomes after UCB transplantation are similar to those of
recipients of adult donor grafts [1-6], the delay in time to
neutrophil recovery and higher risk of graft rejection remain
as signiﬁcant limitations. Multiple donor grafts [3-6], ex vivo
expansion [7,8], intrabone marrow injection [9,10], and
coinfusion with haploidentical CD34þ selected hematopoi-
etic stem cells [11,12] have each shown promising results.
However, higher costs and/or the need for special technical
expertise or facilities are limitations of these strategies.
Other areas of active investigation include manipulation of
hematopoietic progenitor cell (HPC) homing through
priming with prostaglandin E2 [13], administration of
dipeptidyl peptidase-4 inhibitor to the patient [14], and
incubation of UCB with fucosyltransferase-VI and GDP-
fucose, a process known as ﬂucosylation [15].
Preclinical data demonstrated that priming CD34þ HPC
with complement fragment 3a (C3a) increased in vitro
stromal derived factor 1aemediated transwell migration,
and improved homing and engraftment in murine models
[16-18]. Additional studies showed that C3a priming of
CD34þ HPCs resulted in the incorporation of the CXCR4edgments on page 1479.
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13.07.016receptor into membrane lipid rafts [19], its active form. Thus,
C3a-mediated activation of CXCR4 provides a mechanistic
explanation for the improvement in stromal derived factor-
1aemediated migration, homing, and engraftment observed
in themurinemodels. Thus, we hypothesized that priming of
UCB hematopoietic progenitors with C3a would facilitate
homing and could potentially be used to improve engraft-
ment after myeloablative single UCB transplantation.
However, before we tested it in the single UCB graft setting,
we ﬁrst sought to establish the safety of C3a priming. We
report here on the safety and preliminary efﬁcacy proﬁle of
C3a priming of UCB grafts in patients undergoing non-
myeloablative double UCB transplantation for advanced and
high-risk hematological malignancies.PATIENTS AND METHODS
Patients
Patients 18 to 75 years old who were candidates for a nonmyeloablative
double UCB transplantation for the treatment of an advanced or high-risk
hematological malignancy were eligible for this study. Patients were also
required to have adequate organ function, deﬁned as absence of decom-
pensated congestive heart failure or uncontrolled arrhythmia and left
ventricular ejection fraction 35%; corrected carbon monoxide diffusing
lung capacity >30% of predicted, and absence of O2 requirements; trans-
aminases and bilirubin<5 times upper limit of normal, creatinine2mg/dL
and for patients with a creatinine>1.2 mg/dL or history of renal dysfunction
an estimated or measured glomerular ﬁltration rate >40 mL/min/1.73m2.
Additional eligibility criteria included Karnofsky score 60, absence of
uncontrolled serious infections and, if the patient underwent prior mye-
loablative autologous transplantation, must be >3 months from that
procedure. The treatment protocol was approved by the institutional
review board of the University of Minnesota and registered at http://
www.clinicaltrials.gov (NCT#00963872). All patients provided written
informed consent following the principles of the declaration of Helsinki.Transplantation.
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The treatment plan is summarized in Figure 1. All patients received
a conditioning regimen that consisted of single dose of cyclophosphamide
50mg/kgonday6,ﬂudarabine40mg/m2dailyondays6 to2, anda single
fraction of total body irradiation 200 cGywithout shielding on day1. Equine
antithymocyte globulin (ATGAM, Pharmacia, Kalamazoo, MI) at 15 mg/kg
every12hoursondays3 to1was added in a subpopulationofpatientswho
had received fewer than 2 cycles of multiagent chemotherapy within the
3 months before enrollment and no prior autologous transplantation, as
described [20]. Immune suppression consisted of cyclosporine twice daily
from day 3 for at least 3 months with target trough levels of 200 ng/mL to
400 ng/mL and mycophenolate mofetil at 1 g intravenously or orally twice
daily from day 3 to þ30. Supportive care followed institutional guidelines
andhasbeenpreviously described [20]. Granulocyte-colonystimulating factor
(5 mg/kg/day) from day 0 was administered to all patients until the absolute
neutrophil count was >2500/uL for 2 consecutive measurements.
UCB Graft Selection
Patients were required to have 3 UCB units identiﬁed and HLA-matched
at 4 to 6 antigenswith the recipient and each other, considering HLA-A and B
at the antigen level and DRB1 at the allele level, according to our institu-
tional algorithm. The 2 UCB units composing the double UCB graft were
required to have a minimum combined cryopreserved nucleated cell dose
3  107/kg, with each unit having a minimum cell dose of 1.5  107/kg, as
described [20]. These 2 units were transported to the transplantation center
via overnight delivery in a dry shipper previously cooled by liquid nitrogen
(temperature < 150C) before the initiation of the preparative regimen
and then maintained in the vapor phase of liquid nitrogen until the day of
transplantation. Units were thawed using the method described by
Rubinstein et al. [21]. The third UCB was reserved and conﬁrmatory typing
was completed before the start of the conditioning regimen to serve as
a backup in case the C3a-primed unit did not pass lot release; however, this
unit was not required to be on site. If lot release criteria were not achieved,
the patient would not have received the product and the backup unit would
have been immediately requested and infused within 72 hours.
C3a Priming
One of 2 UCB units was primed with C3a (Calbiochem, CA) manufac-
tured from serum sourced from volunteer, noncompensated donors
collected at a US-licensed blood center. C3a was supplied as lyophilized
product that was prepared by adding 1 mL of 5% dextran/5% albumin. After
thawing, the cord blood unit was resuspended in dextran/albumin and
primed with the C3a at ﬁxed 1mg/mL concentration at room temperature for
15 minutes. The C3a concentration for priming was based in murine studies
[18]. After undergoing lot release testing, the C3a-primed UCB unit was
released for transplantation with no further washing. Lot release testing
included a negative-gram stain, endotoxin <5.0 EU/kg, and acridine orange
and propidium iodide viability 45%.
UCB Infusion
All patients received premedication with acetaminophen and diphen-
hydramine and intravenous hydration [20]. The unmanipulated UCB unitFigure 1. This ﬁgure summarizes the treatment plan of the studywas infused ﬁrst through a central line without in-line ﬁltration [20]. The
C3a-primed UCB unit was infused second, within 30 minutes of the
completion of the infusion of the unmanipulated UCB unit, in an identical
manner.
Infusional Toxicity and Safety Monitoring
Patients were monitored for 24 hours for evidence of infusional adverse
events (as deﬁned by Common Terminology Criteria for Adverse Events 4.0).
In addition, in the ﬁrst 17 patients, blood was drawn before infusion and at
15, 30, and 60 minutes after infusion to monitor for the activation of path-
ways downstream of C3a (coagulation, interleukin-6, tumor necrosis factor-
alpha, histamine, tryptase, and C-reactive protein). Stopping guidelines
were in place for excess graft failure, severe graft-versus-host disease,
treatment-related mortality and infusional toxicity.
Statistical Considerations
Design
In the ﬁrst 22 patients enrolled in this study, the smaller unit was to be
primed with C3a; however, in one of these patients, the larger unit was
primed. Safety was assessed by monitoring the infusional toxicity proﬁle,
lack of activation of downstream pathways, and the ability of C3a-primed
UCB units to engraft. In September 2011, after 22 patients had been
treated, the study was amended to an open label 1:1 randomization so that
both the unit with the lower and the higher cell dose had an equal chance of
being primed with C3a. However, after an interim analysis showed no effect
of C3a priming on day þ100 unit predominance, the study was closed to
accrual.
Study endpoints and deﬁnitions
The primary endpoints were incidence of infusional toxicity after the
infusion of 2 UCB units, 1 of which had been primed with C3a fragment, and
the proportion of patients with the C3a unit predominating at day þ100
chimerism studies. A unit was considered the predominant unit if it rep-
resented 70% of the bone marrow chimerism as described [22]. Secondary
endpoints were incidence of absolute neutrophil recovery, deﬁned as
absolute neutrophil count  500/mL in association with partial or complete
chimerism by 42 days after transplantation; time to platelets >20,000/mL,
deﬁned as the ﬁrst of 7 consecutive days with platelet count >20,000/mL
without platelet transfusions; chimerism determining the relative contri-
bution of donor hematopoiesis; cumulative incidence of nonrelapse
mortality (NRM); and progression-free survival (PFS), deﬁned as survival in
the absence of disease relapse or progression.
Statistical Analysis
Variables related to patient, disease, UCB graft, and transplantation
characteristics were reported descriptively. Comparison between the
unmanipulated and C3a-primed UCB units used the general Wilcoxon rank-
sum test for continuous variables and the chi-square test or Fisher’s exact
test for categorical variables. Probability of PFS was calculated using the
Kaplan-Meier estimator [23]. For analyses of PFS, relapse, progression or
death from any cause were considered an event. Patients alive in continuous
remission were censored at last follow-up. Probabilities and 95% conﬁdencepriming 1 of 2 UCB units with complement fragment 3a.
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using the cumulative incidence function [24]. For neutrophil and platelet
recovery, death from any cause without the event was the competing event,
and for nonrelapse death, relapse was the competing event. We tested
whether the probability of unit predominance by the C3a-primed unit was
equal to 50% by using the normal approximation for sample proportions to
calculate the standard deviation [25]. To further determine if there was an
effect of C3a priming, we compared neutrophil engraftment, platelet
engraftment, and PFS of subjects in this study with historical controls from
our institution who received the same conditioning regimen and immune
suppression. Statistical comparison of time-to-event between study subject
and historical control curves was completed by the log-rank test.RESULTS
Patient and Graft Characteristics
Patient and double UCB graft characteristics are summa-
rized in Table 1. Among 29 patients treated, the median age
was 58 years and the median weight was 78 kg. Approxi-
mately one half of the patients had acute leukemia,
two-thirds were male, and 18 were cytomegalovirus sero-
positive. One patient was evaluable only for infusional
toxicity, as his unmanipulated UCB unit was damaged during
processing and he received a backup unit, and in 1 patient
the unit selected for priming had a post-thaw viability below
lot release even before C3a priming and was replaced.
Characteristics of the C3a-primed and unmanipulated unitsTable 1
Patient, Transplantation and Umbilical Cord Blood Unit Characteristics of
Patients Receiving One of Two Units Primed with C3a
Factor Value
Number of patients 29
Age, median (range) yr 58.2 (20.9 to 71.9)
Weight, median (range), kg 78.4 (48.4 to 109.4)
Patient Gender
Male 18 (62%)
Female 11 (38%)
Diagnosis
Acute lymphoblastic leukemia 2 (7%)
Acute myeloid leukemia 13 (45%)
Chronic lymphocytic leukemia 1 (3%)
Myelodysplastic syndrome 6 (21%)
Hodgkin’s/Non-Hodgkin’s lymphoma 6 (21%)
Multiple myeloma 1 (3%)
High-risk disease* 13 (45%)
Conditioning with antithymocyte globulin 5 (17%)
CsA/MMF graft-versus-host disease
prophylaxis
29 (100%)
Combined total nucleated cell dose
( 108/kg), median (range)
.40 (.29 to 0.66)
Combined CD34þ cell dose ( 106/kg),
median (range)
.76 (.33 to 3.54)
Combined CD3þ cell dose ( 107/kg),
median (range)
1.4 (1.0 to 3.0)
UCB unit/donor HLA disparity
4/6 þ 4/6 5 (17%)
4/6 þ 5/6 5 (17%)
5/6 þ 5/6 10 (34%)
5/6 þ6/6 6 (21%)
6/6 þ 6/6 3 (10%)
Follow-up of survivors, median (range) d 406 d (365 to 800)
CsA indicates cyclosporine A; MMF, mycophenolate mofetil; UCB, umbilical
cord blood.
Data presented are n (%) unless otherwise indicated.
* Disease risk at the time of hematopoietic cell transplantation was
classiﬁed into standard risk or high risk based on the ASBMT RFI 2006 risk
scoring schema (http://www.asbmt.org). Acute leukemia in ﬁrst or second
complete remission; chronic myelogenous leukemia in ﬁrst chronic phase;
Hodgkin’s or non-Hodgkin’s lymphoma in complete or partial chemo-
therapy sensitive remission, chronic lymphocytic leukemia in ﬁrst remis-
sion, myelodysplastic syndrome, or myeloproliferative disorder without
excess blasts were considered standard risk. All others determined to be
high risk at the time of transplantation.are summarized in Table 2. In accordance with the study
design, the C3a-primed unit had lower total nucleated cell
and CD3þ cell doses. CD34þ cell dose was similar between
the C3a-primed and unmanipulated unit. At the time of
thaw, median viability was similar between the C3a-primed
and unmanipulated units; however, at the end of priming
procedure median viability was lower in the C3a-primed
units as compared to post-thaw viability of the unmanipu-
lated unit (P ¼ .05). The HLA and gender disparity between
the C3a-primed and the unmanipulated UCB unit were
similar.
Infusional Toxicity
All C3a-primed units passed lot release testing and were
infused according to the treatment plan. All patients were
evaluable for infusional toxicity that was determined before
and 24 hours after the infusion of the C3a-primed UCB unit.
In 17 (57%) patients, we observed no change in the grade of
pre-existing or new adverse events. New and increased
hypertension were the only notable infusional adverse
events observed in 9 (30%) patients; grade 1 in 2 patients,
grade 2 in 4 patients, and grade 3 in 3 patients. Even before
the infusion of the C3a-primed unit, hypertension was
observed in 26 patients: grade 1 in 9 patients, grade 2 in
8 patients, and grade 3 in 9 patients. There were 9 additional
grade 1 adverse events after infusion of the C3a-primed unit:
hypotension in 2 patients; and back pain, bradycardia, con-
stipation, QT prolongation, chills, hypoxia, and dyspnea, all in
1 patient. Based on the validation runs, there was minimal
residual C3a at the end of priming (data not shown), and
because C3a has a plasma half-life of <5 minutes, as part of
the protocol safety, we monitored for evidence of activation
of pathways downstream of C3a. In the ﬁrst 17 patients,
peripheral bloodwas obtained at 15, 30, and 60minutes after
infusion of the C3a-primed UCB unit for coagulation testing,
IL-6, TNF-alpha, histamine, tryptase and C-reactive protein
levels (Figure 2A-I). Overall, there was no signiﬁcant change
in any of these parameters as compared to before the infu-
sion of the pre-C3a-primed unit.
Hematopoietic Recovery and UCB Unit Predominance
The cumulative incidence of neutrophil engraftment was
93% (95% CI, 84% to 100%) at a median of 7 days (range, 0 to
26 days). Of the 27 of 29 patients who had neutrophil
engraftment by dayþ42 after transplantation, 9 patients had
hematopoiesis predominantly from the C3a-primed unit and
18 from the unmanipulated unit. In the 4 patients that it was
primed, the larger unit did not predominate in any of them.
Among the 5 patients who received ATG as part of the
conditioning regimen, 2 had predominance of the primed
unit, and 1 was not evaluable. One patient (unique patient
number [UPN] 5493) with mixed donor chimerism at
day þ21 was considered “graft failure” at day 41 for lack of
neutrophil recovery and had relapsed acute myelogenous
leukemia on day þ49; 1 patient (UPN 5611) had relapsed
leukemia at day þ13. The median time of neutrophil
recovery was 7 days (range, 6 to 19) and 7 days (range, 6 to
26 days) for patients whom the C3a-primed and the unma-
nipulated unit predominated at day þ21, respectively. The
cumulative incidence of platelet recovery >20,000/mL
at 60 days after transplantation was 79% (95% CI, 58% to
100%); 67% (95% CI, 33% to 100%) in patients with the C3a-
primed unit predominating, and 94% (95% CI, 69% to
100%) for the unmanipulated unit group (P ¼ .25). In the
nonmyeloblative setting, there is transient autologous
Table 2
Characteristics of the C3a-Primed and Unmanipulated Umbilical Cord Blood Units
Factor C3a-Primed Unmanipulated P Value
Total nucleated cell dose ( 108/kg) , median (range) .15 (.08 to 0.47) .25 (.11 to .49) <.001
CD34þ cell dose ( 106/kg), median (range) .32 (.06 to 3.23) .34 (.13 to 1.08) .89
CD3þ cell dose ( 107/kg), median (range) .5 (.3 to 1.3) .8 (.4 to 2.6) <.001
Post-thaw viability, median (range) 69% (47% to 81%) 72% (48% to 88%) .28
Post-C3a priming viability, median (range) 63% (50% to 78%) NA .005*
UCB unit/Donor HLA Disparity
4/6 7 (24%) 8 (28%) .95
5/6 16 (55%) 15 (52%)
6/6 6 (21%) 6 (21%)
Male Donor 15 (52%) 11 (38%) .29
* P value refers to the comparison between the post-thaw viability of the unmanipulated unit and the viability after C3a priming.
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differences in time to hematopoietic recovery. Importantly,
we observed no deleterious effect of C3a priming on the rate
of neutrophil and platelet recoveries as compared with
historical controls (Figure 3A-B). Twenty-one patients
survived at least 100 days and were evaluated for bone
marrow chimerism; the C3a-primed unit predominated in
6 patients. Three of the patients who had shown predomi-
nance of the C3a-primed at day þ21 were not evaluable at
day þ100: 2 died and 1 relapsed before day þ100. One
additional patient who died at dayþ87 had peripheral blood
CD3þ cell chimerism showing predominance of the C3a-
primed unit.
Mortality and Survival
At 1 year, the cumulative incidence of NRM was 10% (95%
CI, 0 to 21%) and the probability of PFS was 52% (95% CI, 33%
to 68%); similar to that of historical controls (Figure 3C-D).
DISCUSSION
We studied whether priming with C3a would be safe and
potentially improve hematopoietic engraftment after UCB
transplantation. The main observation was that priming of
UCB with C3a was safe as measured by the mild infusional
toxicity proﬁle and the lack of activation of downstreamFigure 2. Coagulation, cytokine and inﬂammatory response marker levpathways. We also observed the ability of C3a-primed units
to engraft long term in about one third of patients with no
adverse impact on survival.
Themost frequently observed infusional toxicity wasmild
to moderate hypertension, mostly grades 1 and 2. However,
hypertension is not unexpected, and although it is likely
related to the infusion of the C3a-primed unit, it can, at least
in part, be attributed to the infused volume of the unit and
the ﬂuid hydration that all patients received for 24 hours
after the infusion in addition to their treatment with cyclo-
sporine. All other infusional toxicities in the 24-hour obser-
vation period were mild, expected, and possibly related to
other transplantation procedures. This minimal infusional
toxicity, along with the data showing no activation of path-
ways downstream of C3a, demonstrated a favorable safety
proﬁle that could be used as a benchmark for future studies
using modiﬁed C3a priming methods, longer incubation
periods, or higher C3a concentrations.
Our goal was to develop a simple and inexpensive
strategy that could eventually be used to shorten time to
neutrophil recovery and reduce the risk of graft failure. We
chose to conduct our phase I study in the nonmyeloablative,
double UCB setting to provide added safety. First, after
nonmyeloablative conditioning there is the potential for
autologous reconstitution in case of graft rejection. Second,els monitored after the infusion of the the C3a primed UCB unit.
Figure 3. Clinical outcomes of patients treated in the study priming 1 of 2 UCB units with C3a as compared to historical controls.
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unmanipulated unit could still engraft in case the C3a
priming had an adverse effect on UCB units not detected by
lot release testing. Last, we had historical data to benchmark
outcomes such as hematopoietic engraftment and PFS.
We have reported that after a period of mixed chimerism,
97% of double UCB recipients have a single predominant unit
by day þ100 after transplantation [22]. A higher CD3þ cell
dose predicted the long-term predominant unit 70% of the
time. Studying clinical samples from patients who received
double UCB transplants, we also found that most CD34þ cells
in UCB expressed CXCR4. However, the intensity of surface
expression of CXCR4 by itself did not predict the predomi-
nant unit [26]. In contrast, our preclinical data had shown
that C3a priming of CD34þ progenitors led to incorporation
of the CXCR4 chemokine receptor in membrane lipid rafts
[19], its active form resulting in increased transwell migra-
tion towards a stromal-derived factor 1a gradient plus
improved homing and engraftment in murine models
[16-18]. Our double UCB platform also allowed the use of
background data on chimerism and long-term unit
predominance as surrogate measures of efﬁcacy. If C3a
priming was robust enough to skew long-term predomi-
nance towards the primed units with smaller CD3þ cell dose,
as we did in 25 (83%) of the patients, it would be indirect
evidence of efﬁcacy, thus, supporting testing of this strategy
in the myeloablative single UCB setting. We also considered
the possibility that C3a priming could favor homing and early
neutrophil recovery by the treated unit with later hemato-
poiesis being derived from the unmanipulated unit.
However, the C3a-primed unit did not predominate on bone
marrow chimerism either early at day þ21 or day þ100
compared with our background data [22]. Thus, although
UCB C3a priming was clearly safe, the C3a-primed unit pre-
dominated in only one third of cases, similar to that in
unmanipulated grafts. This suggests that, as tested, C3a
priming was not effective in promoting homing of stem cells
and engraftment.
We can speculate as to the many factors that may have
contributed to this lack of clinical efﬁcacy. We tested UCB C3apriming in the nonmyeloablative setting, where early neutro-
phil recovery has an autologous reconstitution component.We
could not use time to neutrophil recovery as an endpoint and
used skewing of long-term predominance towards the C3a-
primed unit as a surrogate. Available data support a role of
CD3þ cells in the determination of predominance after double
UCB transplantation [22,27,28]. It is possible that the effect of
C3a primingwas not sufﬁcient to overcome the immunological
mechanism of UCB predominance from the larger CD3þ
inoculum in the unmanipulated unit. Based on our preclinical
studies, we tested a ﬁxed C3a concentration at room temper-
ature for UCB priming. We cannot rule out that higher C3a
concentrations incubated at 37C may be required to improve
human transplantation. We also observed slightly lower
median viability of the C3a-primed unit before infusion.
Whether the lower viability in the C3a-primed units is a result
of either the priming process or a random observation, the
difference of viability in favor of the unmanipulated unit could
have contributed to the long-term predominance by the
unmanipulated unit [29]. Nonetheless, the rate of predomi-
nance of the smaller unit we observed in this studywas similar
to that of our background data [22].
Strategies targeting homing of UCB hematopoietic
progenitors have the advantage of simplicity and low cost
[13-15]. Similar to our study, priming of UCB with prosta-
glandin E2 has been tested [13]. In contrast to our study, after
priming the smaller unit in a pilot study and demonstrating
safety, the investigators then modiﬁed the conditions,
adjusting temperature and length of the priming procedure
[13]. At this stage, they also primed the larger of 2 UCB units
and found that the prostaglandin E2etreated unit most
frequently predominated, suggesting clinical efﬁcacy. The
DDP-4 inhibitor study is the only 1 studied in the setting of
myeloablative single UCB transplantation [14]. Similar to our
study, dipeptidyl peptidase-4 inhibitionwas safe, but further
studies are required to demonstrate efﬁcacy. The fucosyla-
tion approach is soon to start clinical testing [15]. The goal of
all these strategies is provide reproducible, fast engraftment.
Although this has been achieved in ex vivo expansion
studies, current methodology still requires a current good
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lated UCB unit to provide long-term engraftment; thus,
increasing rather than decreasing the upfront cost of
the procedure [7,8]. We cannot rule out that future
achievement of short time to neutrophil recovery with long-
term engraftment may be achieved by combining low-cost
homing enhancement with ex vivo expansion.
In summary, we found that the infusion of C3a-primed
units was safe and did not impair engraftment and we also
observed no deleterious effect on clinical outcomes as
compared with historical controls. However, as we did not
observe skewing of the long-term predominance towards
the C3a-primed unit as surrogate evidence of efﬁcacy, further
studies to optimize the priming methodology or alternatives
to enhance HPC homing are needed.
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